Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Serono/Takeda Matuzumab Development In Question After Phase II Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Study evaluating the monoclonal antibody failed to meet its endpoint in metastatic colorectal cancer patients.

You may also be interested in...



Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor

Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.

Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel